全文获取类型
收费全文 | 957篇 |
免费 | 87篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 2篇 |
妇产科学 | 51篇 |
基础医学 | 10篇 |
口腔科学 | 3篇 |
临床医学 | 28篇 |
内科学 | 79篇 |
皮肤病学 | 2篇 |
神经病学 | 24篇 |
特种医学 | 16篇 |
外国民族医学 | 1篇 |
外科学 | 40篇 |
综合类 | 66篇 |
预防医学 | 13篇 |
眼科学 | 229篇 |
药学 | 84篇 |
2篇 | |
中国医学 | 1篇 |
肿瘤学 | 420篇 |
出版年
2024年 | 4篇 |
2023年 | 23篇 |
2022年 | 32篇 |
2021年 | 42篇 |
2020年 | 48篇 |
2019年 | 42篇 |
2018年 | 45篇 |
2017年 | 60篇 |
2016年 | 53篇 |
2015年 | 62篇 |
2014年 | 119篇 |
2013年 | 89篇 |
2012年 | 101篇 |
2011年 | 83篇 |
2010年 | 56篇 |
2009年 | 87篇 |
2008年 | 82篇 |
2007年 | 31篇 |
2006年 | 16篇 |
2005年 | 7篇 |
2003年 | 1篇 |
排序方式: 共有1083条查询结果,搜索用时 15 毫秒
81.
前房注射Bevacizumab治疗虹膜红变的疗效观察 总被引:3,自引:0,他引:3
目的:观察眼前房注射Bevacizumab(avastin)对虹膜红变的疗效及安全性。方法:5例(5眼)虹膜红变者分别继发于糖尿病视网膜病变,静脉周围炎,静脉阻塞。其中2例为玻璃体切割术后硅油填充眼,给予前房注射0.03ml(0.75mg)Bevacizumb(avastin)。其中1例联合小梁切除手术,1例联合睫状体冷凝术。结果:所有手术眼虹膜新生血管迅速消退,眼内压在联合使用抗青光眼手术或药物后降低,随访2~5mo没有虹膜红变复发,眼内压控制良好。结论:前房注射Bevacizumab(avastin)有效地减轻了虹膜红变,特别是在一些不适合玻璃体腔注射的病例,短期的研究随访证实前房注射迅速消退虹膜新生血管且无明显副作用。 相似文献
82.
83.
84.
J.J. Pérez-Santonja E. Campos-Mollo M. Lledó-Riquelme L. Fernández-Sánchez N. Cuenca-Navarro 《Archivos de la Sociedad Espa?ola de Oftalmología》2013,88(12):473-481
ObjectiveTo evaluate the effects of topical bevacizumab and topical sunitinib on vascular microdensity and morphology of corneal neovascularization (NV).MethodsA total of 33 rabbits were distributed into 3 groups: group 1 (control; n=11): saline; group 2 (n=11): bevacizumab 5 mg/ml; and group 3 (n=11): sunitinib 0.5 mg/ml. A corneal NV model was used, based on sutures in the right eye of each rabbit. Each treatment was administered topically 3 times daily for 14 days. Corneas were then processed for the study of vascular microdensity (6 eyes) and vascular morphology analysis (5 eyes) using enzymatic staining histological techniquesResultsThe vascular response in group 3 was limited to small-sized tree formations with various vascular axes compared with the extensive, lush and directional corneal NV of group 1 and 2. In the histological sections near the limb, there were no differences in vascular microdensity studies between the three groups. However, the mean sectional area of vessels (MSAV) in group 3 was 41.88% lower than in group 1 and 19.19% lower than in group 2. In distal sections, there were no differences between groups 1 and 2. However, group 3 was characterized by absence of vessels.ConclusionsBevacizumab produced no changes in the morphology of the vessels or the vascular microdensity. Sunitinib reduced the size of the new vessels and induced changes in the vascular tree. 相似文献
85.
《Seminars in ophthalmology》2013,28(5-6):355-360
AbstractIntroduction: Age-related macular degeneration is a major cause of blindness among people aged 50 and older in industrialized countries. Anti-VEGF therapy has been tremendously successful in the treatment of neovascular macular degeneration. Examining the pharmacogenetics of patients’ response to the anti-VEGF molecules could allow for a tailored treatment strategy based on patients’ underlying genetics rather than the “one-size fits all” approach currently used. Methods: Review of the English literature for papers examining the pharmacogenetics of treatment response of neovascular macular degeneration to either ranibizumab or bevacizumab. Polymorphisms in CFH, ARMS2, HTRA1 and VEGF A were examined and reviewed. Results: Patients with the high-risk CC genotype in complement factor H (CFH) had a worse response to therapy with ranibizumab and bevacizumab. No clear trends were found with ARMS2, HTRA1 and VEGF A. Conclusions: The goal of personalized medicine is to craft a treatment program that is ideally suited to an individual patient’s disease and genetic make-up rather than simply what works for a large population who share similar disease characteristics. Continued research is needed to achieve this goal for the treatment of age-related macular degeneration. 相似文献
86.
目的 研究贝伐珠单抗(bevacizumab,Bev)联合化疗治疗转移性结直肠癌的近期疗效和安全性.方法 对43例接受贝伐珠单抗联合化疗治疗的晚期结直肠癌患者进行回顾分析,评价联合治疗的近期疗效及不良反应.结果 43例患者中部分缓解(PR)17例,疾病稳定(SD)19例,疾病进展(PD)7例;中位无进展生存(PFS)为10.3个月.3~4度不良反应主要为白细胞和粒细胞减少及恶心、呕吐.与贝伐珠单抗相关的不良反应为蛋白尿、高血压、鼻出血、经血增加、肠道出血、肠穿孔及静脉血栓等.结论 贝伐珠单抗联合化疗治疗晚期结直肠癌近期疗效较好,不良反应可耐受,远期疗效有待进一步观察. 相似文献
87.
Although the inhibition of angiogenesis is an established modality of cancer treatment, concerns regarding toxicity and drug resistance still constitute barriers to be overcome. For almost a decade since the approval of bevacizumab in 2004, the efforts on antiangiogenic therapeutics have been mainly focused in inhibiting the VEGF pathway. The ongoing understanding of the complexity of the angiogenic process has broadened the spotlight to include concurrent and downstream players to the list of targeted inhibitors. In this review, we summarize the currently existing and the promising antiangiogenic treatments, envisioning an apparent evolutionary trend towards the development of angiogenesis inhibitors of three modalities: single-target, multi-target, and broad-spectrum agents. The clinical efficacy and some structural aspects of monoclonal antibodies, small molecules, endogenous and synthetic angiogenesis inhibitors and their molecular targets are discussed, and the targeting of endothelial cells with the use of cytotoxic drugs in a metronomic schedule is appraised. The reader is invited to revisit current expectations about antiangiogenic therapy in an attempt to set consistent clinical endpoints from which patients could gain real and lasting clinical benefits. 相似文献
88.
Oliver Gautschi Sacha I. Rothschild Qiyu Li Klazien Matter-Walstra Alfred Zippelius Daniel C. Betticher Martin Früh Rolf A. Stahel Richard Cathomas Daniel Rauch Miklos Pless Solange Peters Patrizia Froesch Thilo Zander Martina Schneider Christine Biaggi Nicolas Mach Adrian F. Ochsenbein 《Clinical lung cancer》2017,18(3):303-309
Background
Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non–small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone.Patients and Methods
We conducted a nonrandomized phase II trial with 2 sequential cohorts. In the first cohort, 77 patients were treated with 4 cycles of cisplatin, bevacizumab, and pemetrexed every 3 weeks, followed by bevacizumab plus pemetrexed maintenance until progression. In the second cohort, we treated 52 patients without bevacizumab, using maintenance with pemetrexed alone. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), adverse events, and the treatment costs of the 2 cohorts were compared.Results
The median PFS from the time of registration was 6.9 months in cohort 1 and 5.6 months in cohort 2. The ORR was 62.3% in cohort 1% and 44.2% in cohort 2. The PFS (hazard ratio, 0.7; 95% confidence interval [CI], 0.5-1.0; P = .041) and ORR (odds ratio, 2.1; 95% CI, 1.0-4.3; P = .049) were better in cohort 1 than in cohort 2. No OS difference was found (hazard ratio, 1.0; 95% CI, 0.7-1.6; P = .890) after a median follow-up period of 47 months for cohort 1 and 27 months for cohort 2. The rate of grade ≥ 3 adverse events was greater in cohort 1. The treatment costs per patient were on average 1.4 times greater for cohort 1.Conclusion
The addition of bevacizumab increased the ORR and PFS, but not OS, in our nonrandomized trial. Furthermore, the addition of bevacizumab was associated with greater toxicity and higher costs. 相似文献89.
目的 观察贝伐珠单抗联合FOLFOX或FOLFIRI方案用于转移性结直肠癌一线及二线治疗的临床疗效和毒副反应。方法 回顾性分析2005年11月至2012年8月接受贝伐珠单抗联合FOLFOX或FOLFIRI方案作为一线及二线治疗的57例转移性结直肠癌患者的临床资料。采用RECIST 1.1版评价疗效,用NCI-CTC 3.0版评价不良反应,用Kaplan-Meier法进行生存分析。结果 57例结直肠癌患者中,19例(33.3%)获PR,28例(49.2%)获SD,有效率(RR)为33.3%,疾病控制率(DCR)为82.5%。贝伐珠单抗联合化疗用于一线与二线治疗患者的RR或DCR差异均无统计学意义(P>0.05);贝伐珠单抗联合FOLFOX方案与FOLFIRI方案的RR或DCR差异均无统计学意义(P>0.05)。57例患者的无进展生存期(PFS)及总生存期(OS)分别为8.83个月及14.80个月。一线与二线治疗及贝伐珠单抗联合FOLFOX方案与FOLFIRI方案的中位PFS或OS差异均无统计学意义(P>0.05)。主要不良反应包括白细胞减少、血小板减少及恶心呕吐。贝伐珠单抗相关的不良反应主要包括高血压3例,蛋白尿1例,鼻衄2例,均为1~2级,药物可以控制。结论 贝伐珠单抗联合化疗治疗转移性结直肠癌能够提高治疗疗效,不良反应可以耐受。 相似文献
90.
Angiogenesis is one of the hallmarks of cancer and a crucial requisite in the development of tumors. Interrupting this process by blocking the vascular endothelial growth factor (VEGF) with the monoclonal antibody bevacizumab has been considered a possible breakthrough in the treatment of various types of cancer, especially for advanced disease. However in breast cancer, studies have shown ambivalent results causing debate about the value of this drug. In this article, we review the evidence for anti-angiogenic treatment options for breast cancer, as well as discuss the possible factors limiting the effectiveness of anti-angiogenic agents and offer a recommendation regarding the future research on these therapies for the treatment of breast cancer. 相似文献